Compare Global X Autonomous & Electric Vehicles (DRIV) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Autonomous & Electric Vehicles vs Smith & Nephew plc — how do they compare? Global X Autonomous & Electric Vehicles trades at $35.85, while Smith & Nephew plc trades at $29.81 (market cap $12.54B). The key difference: Smith & Nephew plc pays a 2.65% dividend while Global X Autonomous & Electric Vehicles pays none, and Global X Autonomous & Electric Vehicles is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| DRIV | SNN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $42.53 | $38.70 |
52-Week Low | $25.23 | $28.73 |
Market Cap | — | $12.54B |
Enterprise Value | — | $15.57B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DRIV trades at $35.85, up 0.79% today, with a bullish technical signal from moving averages and oscillators. The stock shows strong momentum, though the 6-day RSI indicates overbought conditions. Recent news highlights global EV sales growth, with DRIV outperforming peers due to its focus on autonomous technology and software, gaining 38% year-to-date according to Seeking Alpha on 2026-05-14.
The outlook remains positive given sector tailwinds, but risks include competitive pressures from Chinese automakers and sensitivity to fuel price fluctuations. Analyst sentiment is bullish, supported by institutional interest in EV and autonomous driving exposure.
Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.
While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
